Key Takeaways
- HEMA, a new collaboration on health technology appraisal dedicated to reviewing and assessing new methods and processes used in HTAs, is gathering pace and is set to identify its first topic for targeted recommendations at the end of February.
- Outputs by HEMA’s working group could lead to changes in assessment methods used by England’s NICE, Canada’s CDA and ICER in the US.
- The pharmaceutical industry will play an advisory role with seats on HEMA’s steering committee. It will offer insight into which topics the working group should develop into white papers and recommendations.
HEMA, the Health Economics Methods Advisory, a recently announced collaboration between health technology appraisal (HTA) bodies in the US (ICER), England and Wales (NICE) and Canada (the CDA), is a step closer to developing important
The advisory coalition was first established in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?